vs
Side-by-side financial comparison of Ameris Bancorp (ABCB) and HAEMONETICS CORP (HAE). Click either name above to swap in a different company.
HAEMONETICS CORP is the larger business by last-quarter revenue ($339.0M vs $314.4M, roughly 1.1× Ameris Bancorp). Ameris Bancorp runs the higher net margin — 35.1% vs 13.2%, a 21.9% gap on every dollar of revenue. On growth, Ameris Bancorp posted the faster year-over-year revenue change (10.0% vs -2.7%). Over the past eight quarters, Ameris Bancorp's revenue compounded faster (2.3% CAGR vs 0.4%).
Ameris Bancorp is an American bank holding company headquartered in Atlanta, Georgia. Through its bank subsidiary, Ameris Bank, the company operates full-service branches in Georgia, Alabama, Florida, North Carolina and South Carolina, and mortgage-only locations in Georgia, Alabama, Florida, North Carolina, South Carolina, Virginia, Maryland, and Tennessee. The company offers online and mobile banking options for both consumers and businesses.
Haemonetics Corporation is a global provider of blood and plasma supplies and services. The company was founded in Natick, Massachusetts by Dr. Allen (Jack) Latham in the 1970s.
ABCB vs HAE — Head-to-Head
Income Statement — Q1 FY2026 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $314.4M | $339.0M |
| Net Profit | $110.5M | $44.7M |
| Gross Margin | — | 59.7% |
| Operating Margin | — | 19.9% |
| Net Margin | 35.1% | 13.2% |
| Revenue YoY | 10.0% | -2.7% |
| Net Profit YoY | — | 19.3% |
| EPS (diluted) | $1.63 | $0.95 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $314.4M | — | ||
| Q4 25 | $307.1M | $339.0M | ||
| Q3 25 | $314.2M | $327.3M | ||
| Q2 25 | $300.7M | $321.4M | ||
| Q1 25 | $285.9M | $330.6M | ||
| Q4 24 | $290.8M | $348.5M | ||
| Q3 24 | $283.8M | $345.5M | ||
| Q2 24 | $300.6M | $336.2M |
| Q1 26 | $110.5M | — | ||
| Q4 25 | $108.4M | $44.7M | ||
| Q3 25 | $106.0M | $38.7M | ||
| Q2 25 | $109.8M | $34.0M | ||
| Q1 25 | $87.9M | $58.0M | ||
| Q4 24 | $94.4M | $37.5M | ||
| Q3 24 | $99.2M | $33.8M | ||
| Q2 24 | $90.8M | $38.4M |
| Q1 26 | — | — | ||
| Q4 25 | — | 59.7% | ||
| Q3 25 | — | 59.5% | ||
| Q2 25 | — | 59.8% | ||
| Q1 25 | — | 58.4% | ||
| Q4 24 | — | 55.5% | ||
| Q3 24 | — | 54.2% | ||
| Q2 24 | — | 52.0% |
| Q1 26 | — | — | ||
| Q4 25 | 45.9% | 19.9% | ||
| Q3 25 | 43.6% | 17.9% | ||
| Q2 25 | 47.4% | 16.8% | ||
| Q1 25 | 39.5% | 21.6% | ||
| Q4 24 | 43.3% | 16.9% | ||
| Q3 24 | 44.4% | 15.0% | ||
| Q2 24 | 42.1% | 11.8% |
| Q1 26 | 35.1% | — | ||
| Q4 25 | 44.2% | 13.2% | ||
| Q3 25 | 33.7% | 11.8% | ||
| Q2 25 | 36.5% | 10.6% | ||
| Q1 25 | 30.8% | 17.5% | ||
| Q4 24 | 42.5% | 10.8% | ||
| Q3 24 | 35.0% | 9.8% | ||
| Q2 24 | 30.2% | 11.4% |
| Q1 26 | $1.63 | — | ||
| Q4 25 | $1.59 | $0.95 | ||
| Q3 25 | $1.54 | $0.81 | ||
| Q2 25 | $1.60 | $0.70 | ||
| Q1 25 | $1.27 | $1.17 | ||
| Q4 24 | $1.35 | $0.74 | ||
| Q3 24 | $1.44 | $0.66 | ||
| Q2 24 | $1.32 | $0.74 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $363.4M |
| Total DebtLower is stronger | — | $1.2B |
| Stockholders' EquityBook value | $4.1B | $911.5M |
| Total Assets | $28.1B | $2.5B |
| Debt / EquityLower = less leverage | — | 1.34× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $363.4M | ||
| Q3 25 | — | $296.4M | ||
| Q2 25 | — | $292.9M | ||
| Q1 25 | — | $306.8M | ||
| Q4 24 | — | $320.8M | ||
| Q3 24 | — | $299.3M | ||
| Q2 24 | — | $344.4M |
| Q1 26 | — | — | ||
| Q4 25 | — | $1.2B | ||
| Q3 25 | — | $1.2B | ||
| Q2 25 | — | $1.2B | ||
| Q1 25 | — | $1.2B | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $4.1B | — | ||
| Q4 25 | $4.1B | $911.5M | ||
| Q3 25 | $4.0B | $849.2M | ||
| Q2 25 | $3.9B | $882.3M | ||
| Q1 25 | $3.8B | $820.8M | ||
| Q4 24 | $3.8B | $906.9M | ||
| Q3 24 | $3.7B | $878.9M | ||
| Q2 24 | $3.6B | $905.4M |
| Q1 26 | $28.1B | — | ||
| Q4 25 | $27.5B | $2.5B | ||
| Q3 25 | $27.1B | $2.4B | ||
| Q2 25 | $26.7B | $2.5B | ||
| Q1 25 | $26.5B | $2.5B | ||
| Q4 24 | $26.3B | $2.5B | ||
| Q3 24 | $26.4B | $2.5B | ||
| Q2 24 | $26.5B | $2.5B |
| Q1 26 | — | — | ||
| Q4 25 | — | 1.34× | ||
| Q3 25 | — | 1.44× | ||
| Q2 25 | — | 1.39× | ||
| Q1 25 | — | 1.49× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $93.6M |
| Free Cash FlowOCF − Capex | — | $87.2M |
| FCF MarginFCF / Revenue | — | 25.7% |
| Capex IntensityCapex / Revenue | — | 1.9% |
| Cash ConversionOCF / Net Profit | — | 2.09× |
| TTM Free Cash FlowTrailing 4 quarters | — | $308.1M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $390.2M | $93.6M | ||
| Q3 25 | $104.9M | $111.3M | ||
| Q2 25 | $61.4M | $17.4M | ||
| Q1 25 | $116.9M | $116.6M | ||
| Q4 24 | $154.2M | $43.8M | ||
| Q3 24 | $102.2M | $48.8M | ||
| Q2 24 | $-97.1M | $-27.4M |
| Q1 26 | — | — | ||
| Q4 25 | $369.6M | $87.2M | ||
| Q3 25 | $100.5M | $106.3M | ||
| Q2 25 | $53.7M | $13.6M | ||
| Q1 25 | $114.2M | $100.9M | ||
| Q4 24 | $140.7M | $35.2M | ||
| Q3 24 | $99.8M | $39.4M | ||
| Q2 24 | $-100.3M | $-33.1M |
| Q1 26 | — | — | ||
| Q4 25 | 120.4% | 25.7% | ||
| Q3 25 | 32.0% | 32.5% | ||
| Q2 25 | 17.9% | 4.2% | ||
| Q1 25 | 39.9% | 30.5% | ||
| Q4 24 | 48.4% | 10.1% | ||
| Q3 24 | 35.2% | 11.4% | ||
| Q2 24 | -33.4% | -9.8% |
| Q1 26 | — | — | ||
| Q4 25 | 6.7% | 1.9% | ||
| Q3 25 | 1.4% | 1.5% | ||
| Q2 25 | 2.5% | 1.2% | ||
| Q1 25 | 0.9% | 4.7% | ||
| Q4 24 | 4.6% | 2.5% | ||
| Q3 24 | 0.8% | 2.7% | ||
| Q2 24 | 1.1% | 1.7% |
| Q1 26 | — | — | ||
| Q4 25 | 3.60× | 2.09× | ||
| Q3 25 | 0.99× | 2.88× | ||
| Q2 25 | 0.56× | 0.51× | ||
| Q1 25 | 1.33× | 2.01× | ||
| Q4 24 | 1.63× | 1.17× | ||
| Q3 24 | 1.03× | 1.44× | ||
| Q2 24 | -1.07× | -0.71× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ABCB
Segment breakdown not available.
HAE
| Hospital | $143.5M | 42% |
| Plasma Productsand Services | $138.9M | 41% |
| Blood Center Productsand Services | $56.6M | 17% |
